An advisory committee for the Food and Drug Administration has narrowly voted to recommend adding six peptides to an approved list of ingredients that specialty pharmacies can use to custom-mix medications. The decision, reported by ABC News, could reshape how Americans access these compounds by siding with popular demand over warnings from the agency’s own scientists.
During a two-day hearing held on Thursday and Friday, the Pharmacy Compounding Advisory Committee reviewed seven proposed compounds. The panel ultimately voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the regulatory list. Peptides are short strings of amino acids smaller than proteins. While certain peptides like insulin and GLP-1 drugs hold full FDA approval after rigorous testing, the six compounds in question have surged in popularity online without matching clinical data.
The Divide Between Outside Advisers and FDA Reviewers
The votes exposed a sharp philosophical split between the outside panel members and the career scientists within the agency. Six of the eight recently appointed committee members operate clinics that offer peptide treatments to patients. In contrast, FDA staff scientists unanimously opposed adding any of the peptides to the compounding list. Those agency reviewers cited a complete lack of solid clinical trial data, inconsistent manufacturing recipes from batch to batch, and the risk of triggering severe immune reactions.
Supporters on the panel defended their choices as a necessary harm-reduction strategy. They argued that patients are already bypassing traditional channels to purchase these compounds as unregulated research chemicals from overseas online sellers, operating without medical oversight or purity guarantees.
As a physician, I have to make sure that I’m keeping patients as safe as possible. So, when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? That’s what I lose sleep at night over, panel member Dr. Haleem Mohammed said on Thursday.
Public health advocates strongly disagreed with that logic during the public testimony sessions. Critics warned that granting regulatory placement to unproven substances sets a dangerous precedent for drug safety standards in the United States.
Would the government endorse manufacturing heroin because it’s cleaner than what is sold on the street? Dr. Adriane Fugh-Berman, a professor of pharmacology and physiology at Georgetown University, said during public testimony. Just because a market is large doesn’t mean that a product should be legalized. It means that a product should be studied.
The committee did reject a seventh peptide, emideltide, after citing exceptionally weak evidence. Proposed as an under-the-skin injection for narcolepsy and opioid withdrawal, the compound had only been tested via an intravenous route in a single patient case report for narcolepsy and two small, uncontrolled studies for withdrawal.
What Access Means for Patients and the Wellness Industry
Securing a spot on the compounding list does not grant these peptides the status of over-the-counter supplements or declare them officially safe and effective by federal standards. Instead, the recommendation opens a narrow, regulated pathway. Specially licensed compounding pharmacies could legally acquire raw ingredients and prepare custom doses for individuals holding a valid doctor’s prescription.
While pharmacies must verify ingredient origins and test for contamination, these custom mixes still bypass standard FDA protections. They lack ongoing tracking for dangerous side effects and do not carry standardized safety labeling.
The recommendation marks a significant victory for the rapidly expanding telehealth, wellness, and medical spa sectors, which stand to profit from offering the treatments. Conversely, traditional pharmaceutical manufacturers oppose the move, arguing it establishes a loophole around the lengthy clinical trials normally required for medication approval.
FDA Reviews Panel Votes Before Proposing Rules
The advisory panel’s recommendations remain non-binding. Before any policy changes become official, the FDA must review the meeting records, public comments, and vote tallies. The agency will then publish proposed rules and open them for public feedback, a formal rulemaking procedure that can take up to a full year.
However, top public health officials could potentially accelerate that timeline. Robert F. Kennedy Jr., who oversees the FDA as the Health and Human Services Secretary, has previously expressed public support for wider access to peptides, framing existing restrictions as unnecessary barriers that drive patients toward the grey market.
Safety advocates remain concerned that patients will interpret a listing on the compounding registry as an official stamp of regulatory endorsement.
When you write a script for TB-500, what form do you think your patients are getting? Does anyone know? I certainly don’t, Russell Wesdyk, associate director for Regulatory Affairs at the FDA’s Center for Drug Evaluation and Research, said during the hearing. If you don’t know what it is and I don’t know what it is, how do I put it on the list?
As the FDA weighs its next administrative steps following the July 17, 2025, the ultimate fate of peptide compounding rests on how federal leadership reconciles popular market demand with statutory safety requirements.
